Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Istanbul Bakirkoy Maternity and Children Diseases Hospital1,303 enrolled

Overview

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

1,303

Conditions

Pelvic Inflammatory Disease

Interventions

MoxifloxacinDRUG

daily 400 mg moksifloksasin

OfloxacinDRUG

daily 800 mg oflaksasin plus 1000 mg metronidazol treatment

MetronidazoleDRUG

daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID

Eligibility

Sex: FEMALEMin age: 14 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Women diagnosed uncomplicated PID 2. Patients age are between 14 with 45 3. Pelvic tenderness and vaginal discharge Exclusion Criteria: 1. Urinary Tract Enfections 2. Tubo-ovarian abscess and complicated PID 3. Hıstory of antibiotics treatment 4. Other pelvic pain causes 5. Endometriosis 6. Delivery,abortion and surgery within last months

Locations (4)

T.C.S.B. İstanbul Training Research Hospital

Samatya, Fatih, Turkey (Türkiye)

T.C.S.B. Kanuni Sultan Suleyman Training Hospital

Istanbul, Kucukcekmece, Turkey (Türkiye)

T.C.S.B Mardin Women and Children Hospital

Mardin, Mardin, Turkey (Türkiye)

T.C.S.B. Şişli Etfal Training Research Hospital

Şişli, Şişli, Turkey (Türkiye)

Outcomes

Primary Outcomes

Clinically cure

Time frame: 21 Days

Secondary Outcomes

Microbiological cure

Time frame: 21 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.